Minerva anestesiologica
-
Minerva anestesiologica · Dec 2008
ReviewIntrathecal therapy with ziconotide: clinical experience and considerations on its use.
Ziconotide is a synthetic peptide equivalent of an w-conotoxin, obtained from the marine snail Conus magus, which acts by blocking N-type calcium channels in the spinal cord, reducing the perception of pain. It is a newly marketed drug, exclusively for intrathecal use, indicated for severe chronic pain. Ziconotide came to the physicians' table with both doubts and promises; to determine its safety and efficacy, one of the largest and most well-designed randomized double-blind studies in the history of intrathecal therapy was undertaken, and this drug demonstrated efficacy in relieving chronic pain in patients coming from many years of different therapies and therapy failures. ⋯ We noted differences between the well-known activity of morphine on pain and mood, and the more focused action of ziconotide on pain. In addition, it is important to consider the lack of addiction, opioid-induced hyperalgesia and other systemic effects that are common with morphine. These are the reasons why the Polyanalgesic Consensus Conference of 2007 put ziconotide in the first line of intrathecal therapy management.
-
Nutrition support in critically ill patients is not merely simple nutrition, but rather metabolic support. In the last few years, the pharmacological properties of nutrients have been specifically addressed in a new field called pharmaconutrition. This review will offer a deeper insight into this field, focusing on the properties of arginine, glutamine, antioxidants, and omega-3 fatty acids as well as the level of blood glycemia which should be maintained in critically ill patients.